exv10w1





Exhibit 10.1




THIS AGREEMENT is made on June 30, 2008




BETWEEN




UNILIFE MEDICAL SOLUTIONS LIMITED ABN 14 008 071 403, a corporation existing and organized under
the laws of Australia, having its registered office at Level 5, 35 Clarence Street, Sydney, New
South Wales 2000, Australia, represented by Mr Alan Shortall, Director and Chief Executive Officer,
(hereafter referred to as “UNILIFE”)



AND




SANOFl WINTHROP INDUSTRIE, a company existing and organized under the laws of France, having its
registered office at 20, avenue Raymond Aron, 92160 Antony, France, represented by Mr Gilles
Lhemould, Chairman and Chief Executive Officer, and Mr Gérard Touratier, Chief Financial Officer,
(hereafter referred to as “SWIND”), acting on its behalf and on behalf of its Affiliates, and in
particular AVENTIS PHARMA S.A.



UNILIFE MEDICAL SOLUTIONS LIMITED and SANOFl WINTHROP INDUSTRIE may hereinafter collectively be
referred to as, the “Parties” or individually as, the “Party,”



RECITALS




AVENTIS PHARMA SA, and UNILIFE have signed on respectively November 20th 2006 for
AVENTIS PHARMA SA, and December 11, 2006, for UNILIFE a Memorandum of Understanding (“MOU”) in
order to allow AVENTIS PHARMA SA to evaluate certain ready to fill prototype syringes based
on/using UNILIFE’s safety syringe technology with a view to using the Ready to Fill Product Range
utilizing this technology for its pharmaceutical specialties, and have established in said MOU the
principles of the first step of a collaborative technical arrangement in relation to the Ready to
Fill Product Range on an exclusive basis.



The Parties have completed the technical Evaluation of the UNILIFE Ready to Fill Syringes
prototypes provided by UNILIFE to SWIND respectively on 30th march 2008 , and May 5th
2008, and given the results of such Evaluation wish to carry on discussions for the
industrialization and production of Ready to Fill Syringes by UNILIFE on an exclusive basis to
SWIND’s benefit, and to set forth the main terms of their willingness to find an agreement
regarding said potential industrialization and production.



The Parties wish in consequence to conclude the present Agreement for allowing SWIND exclusive
access to the UNILIFE Ready to Fill Syringe safety syringe technology (RTFS) for use in/for RTFS
Market under the conditions herein defined, and defining the following steps of their intended
collaboration, and in particular the negotiation and settlement of the final provisions of an
agreement for the industrial scaling up of the Product (“Industrialisation Agreement”) intended to
be concluded no later than the end of December 2008.



NOW THEREFORE, THE PARTIES AGREE AS FOLLOWS;




Article i — Definitions and Interpretation




In this agreement the following words and expressions have the following meanings:


 


1









 





	 	 	 
	“Affiliate”

	 	shall mean, with respect to either Party,
any corporation, partnership or other
entity controlled by, controlling or under
common control with, such Party, with
“control” meaning direct or indirect
beneficial ownership of more than 50% of
the voting power of, or more than 50%
ownership interest in, such corporation,
partnership or other entity.
	 
	 	 
	“UNILIFE Intellectual Property”

	 	shall mean the Patents, Patent Rights and
Product Know How.
	 
	 	 
	“Industrialization”

	 	shall mean, the finalising of the RTFS
design in collaboration with SWIND and its
Affiliates to ensure that it meets all
necessary requirements for drug
compatibility, filling processes and other
requirements as may be deemed necessary,
including the development of the necessary
processes required to produce the products
on a commercial scale.
	 
	 	 
	“Patents”

	 	shall mean all international and national
patent applications relating to the RTFS
technology and, in particular, number
WO2006108243, WO2006119570, WO2004/082747,
WO2005/72081 and any Patent Rights arising
out of or relating to such patents
applications and relating to the RTFS.
	 
	 	 
	“Patent Rights”

	 	shall mean patent applications or patents,
author certificates, inventor
certificates, utility certificates,
improvement patents and models and
certificates of addition and all foreign
counterparts of them of UNILIFE and
includes any divisions, renewals,
continuations, continuations-in part,
extensions, reissues, substitutions,
confirmations, registrations, revalidation
or additions of or to them, as well as any
supplementary protection certificate in
respect of them, relating to the RTFS.
	 
	 	 
	“Products”

	 	shall mean the existing RTFS for use
in/for the RTFS Market and any variation
in sizes or functionality as may be
developed by SWIND and/or UNILIFE under
this Agreement for use in the RTFS Market.
	 
	 	 
	“Product Know-How

	 	shall mean unpatented technical and other
information including but without
prejudice to the generality of the
foregoing ideas, concepts, inventions,
discoveries, data, formulae,
specifications procedures for experiments
and tests and other protocols, processes,
results of experimentation and testing,
and assay protocols, relating directly or
indirectly to the Products and known to
UNILIFE from time to time, of which
UNILIFE is the proprietor.





 


2









 





	 	 	 
	“RTFS”

	 	shall mean UNILIFE’s Ready to Fill Syringe
safety syringe with integrated auto and
controlled retraction intended to be
supplied to pharmaceutical companies as a
drug delivery device or any parts thereof,
	 
	 	 
	“RTFS Market”

	 	shall mean the market for sterile syringe
products for use for ready to fill or
primary packaged drug delivery solutions.






In this Agreement:



unless the context otherwise requires, all references to a particular article or paragraph shall be
a reference to that article or paragraph, in or to this Agreement as the same may be amended from
time to time pursuant to this Agreement;



headings are inserted for convenience only and shall be ignored in construing this Agreement;
unless the contrary intention appears, words importing the masculine gender shall include the
feminine and vice versa and words in the singular include the plural and vice versa;



unless the contrary intention appears, words denoting persons shall include any individual,
partnership, company, corporation, joint venture, trust, association, organisation or other entity,
in each case whether or not having separate legal personality;



reference to the words “include” or “including” are to be construed without limitation to the
generality of the preceding words; and



reference to any statute or regulation includes any modification or re-enactment of that statute or
regulation.



Article 2 — Intellectual Property Licence




2.1 Subject to the terms of this Agreement, UNILIFE hereby grants to SWIND for the term of this
Agreement an exclusive, royalty free worldwide licence of the UNILIFE Intellectual Property in
order and solely to develop, in collaboration with UNILIFE or have developed in collaboration with
UNILIFE, market, have marketed, use, commercialize, sell or otherwise dispose of and have sold or
have otherwise disposed of the Products for use in/sale to the RTFS Market (“Exclusive Licence”).



For the avoidance of doubt, notwithstanding the Exclusive Licence granted to SWIND, UNILIFE shall
not be precluded from using the UNILIFE Intellectual Property for the purpose of developing,
manufacturing, licensing, selling or otherwise disposing of any products for use in/sale to any
market other than the RTFS Market.



2.2 SWIND shall have the right to sub-licence to Affiliates and to third parties (“SWlND’s
Sub-Licensees”) any of the rights granted hereunder to it without restriction, including the right
to permits SWIND’S Sub-Licensees themselves to sub-licence.



2.3 UNILIFE shall not assign all or any of the UNILIFE Intellectual Property to a third party
(whether an Affiliate or otherwise) without prior to such assignment (a) making such third party
aware of the rights granted to SWIND hereunder and (b) obtaining such third party’s written agreement to take the same subject to the rights granted hereunder.


 


3









 





2.4 Should SWIND or SWIND’s Sub-Licensees wish to sub-licence its Exclusive Licence rights as
outlined in Article 2.1 and Article 2.2 to a third party, SWIND will pay to UNILIFE a portion to be
agreed upon of any fee received or arising from the result of such transaction. For the avoidance
of doubt, the sublicence of its Exclusive Licence rights by SWIND to any of its Affiliates or a
related party shall not give rise to any payment.



2.5 Subject to a successful completion of the different steps of the further intended collaboration
between the Parties, as such collaboration is explained in Article 3 hereafter, UNILIFE retains the
right to be the sole supplier, of the final Products to SWIND and its Affiliates on such terms as
are to be agreed; however, subject to the prior written agreement of UNILIFE and under conditions
to be discussed and agreed upon in good faith between the Parties, SWIND may be able to appoint
additional or alternative suppliers of the Products.



Article 3 -Structure of the further intended collaboration




It is foreseen that the implementation of the intended collaboration between the Parties should
require the Parties to enter into two successive agreements in relation to the Products: the
Industrialisation Agreement, and under the condition precedent of, in particular, the successful
completion of the Industrialisation Agreement, a Supply Agreement.



The present Agreement represents a strong commitment of both Parties to negotiate in good faith
with a view to execute the Industrialisation Agreement within the timeframe reflected below.



On the date of execution of the present Agreement, the Parties have reached further agreement on
certain elements of the Industrialisation Agreement which they consider as essential, though some
pending issues will require further negotiations. The Parties wish therefore to express the current
state of their respective commitments as follows:



• The Parties undertake to negotiate and expect to execute the Industrialisation Agreement by the
end of December 2008.



• SWIND will bear the costs corresponding to the Industrialization and scaling up of the Product,
as such Industrialization and scaling up will be defined in the Industrialisation Agreement.
UNILIFE has provided SWIND with a first estimation of such costs at approximately 15 to 17 Million
Euros. Such amount is provided on an indicative basis and will be subject to review and agreement
between the Parties, it being understood that 17 Million Euros should nevertheless be considered as
the maximum amount of the Industrialization costs to be borne by SWIND under the Industrialisation
Agreement, subject to ascertaining the final Industrialization costs and further negotiations
between the Parties,



Article 4 — Warranties, undertakings and Liabilities




4.1 UNILIFE warrants that to the best of its knowledge, the UNILIFE Intellectual Properly is valid,
and that the marketing, sale or disposal of any Product falling within the scope of the UNILIFE
Intellectual Property does not to the best of UNlLIFE’s knowledge infringe any third party
intellectual property rights. UNILIFE shall promptly inform SWIND of any infringement, or improper
or unlawful use of, or any change to the validity of the UNILIFE Intellectual Property.


 


4









 





4.2 Each Party (“Indemnifying Party”) shall indemnify and hold harmless the other Party (“Indemnified Party”) and its officers, employees and agents at all times in respect of any and all
losses, damages, costs and expenses suffered or incurred as a result of any contractual, tortious
or other claims or proceedings by third parties against Indemnified Party arising out of the
Indemnifying Party’s breach of this Agreement, including breach of representations and warranties,
violation of applicable law, negligence or willful misconduct.



4.3 Neither Party shall be liable to the other in contract torts negligence, breach of statutory
duty or otherwise for any loss, damage, costs or expenses of any nature whatsoever incurred or
suffered by the other of an indirect or consequential nature, including any economic loss or other
loss of turnover, profits, business or goodwill.



4.4 The terms of this Article 4 shall survive expiration or termination of this Agreement for
whatever reason.



Article 5 — Confidentiality




5.1 Both Parties undertake and agree not to at any time for any reason whatsoever disclose or
permit to be disclosed to any third party or otherwise make use of or permit to be made use of the
Product Know How (other than duly authorised under the Agreement), any trade secrets or
confidential information or materials relating to the business affairs or finances of the other or



of any suppliers, agents, distributors, licensees or other customers of the other which comes into
their possession pursuant to this Agreement.



5.2 The obligations of confidence referred to in this Article 5 shall not extend to any
information which the receiving Party demonstrates:



5.2.1 is or shall become generally available to the public otherwise than by reason of a breach by
the recipient Party of such information of the provisions of this Article 5;



5.2.2 is known to the recipient Party of such information and is at its free disposal prior to its
receipt from the other;



5.2.3 is subsequently disclosed to the recipient Party without obligations of confidence by a third
party owing no such obligation of confidentiality to the disclosing Party;



5.2.4 either Party may be required to disclose to a government agency for the purpose of any
statutory, regulatory or similar legislative requirement applicable to the production of Product or
to meet the requirements of any Stock Exchange to which the Parties may be subject, but only to the
extent such disclosure is required, and subject to obligations of secrecy wherever possible; and
only after the disclosing Party has notified the other Party of such requirement sufficiently in
advance to permit said other Party to seek protection of its confidential information; and



5.2.5 can be demonstrated by competent written evidence as having been independently developed by
the recipient of the information in question without access to or use or knowledge of the
information of the disclosing Party.



5.3 The obligations of both Parties under this Article 5 shall survive the expiration or
termination of this Agreement for whatever reason.


 


5









 





Article 6 — Payment




In consideration of the Exclusive Licence granted to SWIND, SWIND shall pay UNILIFE an upfront one
time Exclusive Licence fee of ten (10) millions Euros.



SWIND shall pay such amount invoiced on or before the 31st July 2008 via wire transfer
to a bank account designated in writing by UNILIFE



	 
	Article 7 — Term and termination
7.1 Unless terminated earlier in accordance with the provisions of this Article 7, this







	 
	Agreement shall continue in force for a duration of five years from its execution date. Six
months prior to its term, the Parties will meet in order to discuss the need for and conditions
of a potential renewal of the Agreement; UNILIFE grants SWIND a priority right to such
renewal, subject to good faith and successful negotiation of its terms.
7.2 Either Party may terminate this Agreement forthwith by notice in writing to the other







upon the occurrence of any of the following events:



7.2.1 if the other commits a breach of this Agreement which in the case of a breach capable of
remedy shall not have been remedied within thirty (30) days of the receipt by the other of a notice
in writing identifying the breach and requiring its remedy.



7.2.2 if the other is unable to pay its debts or enters into compulsory or voluntary liquidation
(other than for the purpose of effecting a reconstruction or amalgamation in such manner that the
company resulting from such reconstruction or amalgamation if a different legal entity shall agree
to be bound by and assume the obligations of the relevant Party under this Agreement) or compounds
with or convenes a meeting of its creditors or has a receiver appointed over all or any part of its
assets or takes or suffers any similar action in consequence of a debt, or ceases for any reason to
carry on business.



7.2.3 if the Parties, despite negotiations in good faith, are unable to reach a common
agreement on the terms and conditions of the Industrialisation Agreement within a period of
12 months from the date of this Agreement.



7.3 Should the Agreement be terminated by SWIND in accordance with Article 7.2.2 prior to its term
UNILIFE shall grant SWIND a worldwide, perpetual, royalty-free, sub-licensable, licence on an
exclusive basis, of the UNILIFE Intellectual Property in order and solely to develop or have
developed, market, have marketed, sell, use, commercialize, or otherwise dispose of and have sold
or have otherwise disposed of the Products for use in/sale to the RTFS Market.



7.4 Should this Agreement be terminated pursuant to Article 7.2.3, UNILIFE undertakes to repay the
agreed Industrialization costs received from the date of this Agreement until the date of
termination. The Parties agree, however, that such repayment will be in the form of an agreed
royalty payment on each unit of the Products sold to third parties, for any payment of
Industrialization costs received by UNILIFE in excess of 1 500 000,00 Euros, until such amount is
repaid.


 


6









 





Article 8: Miscellaneous



8.1 Waivers: A waiver of a breach or default under this Agreement shall not be a waiver of any
other or subsequent breach or default. The failure or delay by either Party in enforcing compliance
with any term or condition of this Agreement shall not constitute waiver of such term or condition,
unless such term or condition is expressly waived in writing.



8.2 Force Majeure: except for the failure to pay any money due under this Agreement, neither Party
shall be held in breach of this Agreement by any reason of acts or omissions caused by any act of
God or other causes beyond the reasonable control of the affected Party. The affected Party shall
use due diligence to remove any such causes and to resume performance under this Agreement as soon
as it is reasonably feasible.



8.3 Assignment: This Agreement and the rights and obligations hereunder shall not be assignable by
either Party, including as part of a transfer of assets, without the prior written consent of the
other Party, provided however, that either Party may, without such consent, assign this Agreement
and its rights and obligations hereunder to an Affiliate of such Party. Any permitted assignee
shall assume all obligations of its assignor under this-Agreement.



8.4 Each of UNILIFE and SWIND warrants and undertakes that it is able to enter into this Agreement
and is not restricted by any provisions of any agreements of any nature which prevent it from
carrying out this Agreement fully according to its terms.



8.5 Separate Entities: Nothing in this Agreement shall constitute or be deemed to constitute a
partnership between the Parties hereto or constitute or be deemed to constitute either Party as an
agent of the other for any purpose whatsoever, and neither Party shall have the authority or power
to bind the other Party, or to contract in the name of and create a liability against the other
Party in any way or for any purpose, unless explicitly instructed in writing to do so.



8.6 Notices: All notices, reports and other writings which are required to be given or submitted
pursuant to this Agreement shall be in writing and delivered personally or sent by international
courier service, or by confirmed facsimile transmission, to the addresses set forth below or to
such other address as a Party may from time to time notify to the other Party. Any and all notices
sent to the other Party in accordance with this Article shall become effective as of receipt
thereof by the other Party.



SWIND:



To the attention of the Chief Executive Officer

Sanofi Winthrop Industrie

20, avenue Raymond Aron

92165 Antony

France

Telephone: + 33 1 55 71 71 71

Facsimile:+ 33 1 47 02 50 14




UNILIFE:



Alan Shortall

Unilife Medical Solutions Limited

Level 5, 35 Clarence Street

Sydney, NSW, 2000

Australia

Telephone: +61 2 8346 6500

Facsimile: +61 2 8346 6511

Email: aIan.shortaII@unilife.com.au



 


7









 





8.7 Entire Agreement: This Agreement represents the entire understanding of the Parties with
respect to the subject matter hereof, and supersede all proposals or agreements, oral or written,
and all other communications between the parties related to the subject matter of this Agreement,
including without limitation any representations or warranties made by either Party hereto or its
representatives. This Agreement may not be amended or modified except in a writing duly executed
by the Parties.



8.8 Governing Law: The Parties hereto agree that this Agreement, including without limitation, all
transactions affected hereunder, its validity and enforceability and all relationships between the
Parties in this connection shall be construed under and be governed in all respects by the laws of
New South Wales, Australia.



8.9 Jurisdiction: The Parties hereby agree that any and all disputes arising out of or in
connection with this Agreement shall exclusively submitted to and settled by the courts of New
South Wales, Australia and courts of appeal there from and the Parties hereby submit to such
exclusive jurisdiction.



IN WITNESS WHEREOF this Agreement has been executed and shall take effect on the date set out above




	 	 	 
	UNILIFE MEDICAL SOLUTIONS LIMITED

	 	SANOFI WINTHROP INDUSTRIE
	 
	 	 
	/s/ Alan Shortall

	 	/s/ Gilles Lhernould
	 
	 	 
	Date: July 1, 2008

	 	Date:
	Name: Alan Shortall

	 	Name : Gilles Lhernould
	Title: Director and CEO

	 	Title: President and CEO
	 
	 	 
	 

	 	/s/ Gérard Touratier
	 
	 	 
	 

	 	Date: June 30, 2008
	 

	 	Name : Gérard Touratier
	 

	 	Title: CFO







 


8